News
ORMP
2.340
-0.43%
-0.010
Weekly Report: what happened at ORMP last week (0415-0419)?
Weekly Report · 2d ago
Weekly Report: what happened at ORMP last week (0408-0412)?
Weekly Report · 04/15 10:24
Weekly Report: what happened at ORMP last week (0401-0405)?
Weekly Report · 04/08 10:27
Weekly Report: what happened at ORMP last week (0325-0329)?
Weekly Report · 04/01 10:26
Weekly Report: what happened at ORMP last week (0318-0322)?
Weekly Report · 03/25 10:29
Oramed Pharmaceuticals Welcomes New Audit Committee Chair
TipRanks · 03/18 21:33
Oramed Pharmaceuticals Updates Stock Sale Strategies and Partners
TipRanks · 03/18 21:23
Weekly Report: what happened at ORMP last week (0311-0315)?
Weekly Report · 03/18 10:27
Weekly Report: what happened at ORMP last week (0304-0308)?
Weekly Report · 03/11 10:25
ORMP Stock Earnings: Oramed Pharmaceuticals Beats EPS for Q4 2023
Oramed Pharmaceuticals reported earnings per share of 33 cents. The company did not report any revenue for the quarter. This was above the analyst estimate for EPS of -12 cents. Oramed was not a constituent of the S&P 500 Index in the first quarter.
Investorplace · 03/07 15:53
Oramed Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Oramed Pharmaceuticals Inc reports quarterly adjusted earnings of 33 cents per share for the quarter ended in December. The company reported quarterly revenue of zero; analysts expected zero. The average analyst rating on the shares is "hold" for the company. Oramed pharmaceuticals Inc shares had risen by 41.1% this quarter.
Reuters · 03/07 03:17
Weekly Report: what happened at ORMP last week (0226-0301)?
Weekly Report · 03/04 10:27
Weekly Report: what happened at ORMP last week (0219-0223)?
Weekly Report · 02/26 10:35
Oramed Pharmaceuticals CEO Updates Shareholders on Strategy
TipRanks · 02/20 13:52
Weekly Report: what happened at ORMP last week (0212-0216)?
Weekly Report · 02/19 10:37
MQ, ORMP and EXAI are among pre market gainers
MQ, ORMP and EXAI are among pre market gainers. DIH Holdings US (DHAI) +115%. Beamr Imaging (BMR) +72% NVIDIA team up to accelerate adoption of the newest video standard - AV1. ContextLogic (WISH) +38%.
Seeking Alpha · 02/12 13:34
Weekly Report: what happened at ORMP last week (0205-0209)?
Weekly Report · 02/12 10:30
Weekly Report: what happened at ORMP last week (0129-0202)?
Weekly Report · 02/05 10:35
Top 4 Health Care Stocks That May Crash This Quarter
As of Feb. 2, 2024, four stocks in the health care sector are considered overbought. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength when prices fall. An asset is typically considered over bought when the R SI is above 70, according to Benzinga.
Benzinga · 02/02 13:21
Weekly Report: what happened at ORMP last week (0122-0126)?
Weekly Report · 01/29 10:28
More
Webull provides a variety of real-time ORMP stock news. You can receive the latest news about Oramed Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About ORMP
Oramed Pharmaceuticals Inc. is a pharmaceutical company engaged in the research and development of pharmaceutical solutions with a technology platform. The Company has developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its Protein Oral Delivery (POD) technology is designed to protect drug integrity and increase absorption. Its pipeline includes ORMD-0801 (Oral Insulin) Diabetes, ORMD-0801 (Oral Insulin) NASH, and ORMD 0901 (Oral GLP-1). Its oral insulin (ORMD-0801) has the potential to create a new paradigm in the treatment of diabetes through oral delivery of insulin at an earlier stage of treatment. Its oral insulin capsule (ORMD-0801) has shown a reduction of liver fat content in early clinical trials. It is also developing an oral Glucagon-like peptide-1 (GLP-1) analog capsule (ORMD-0901), which is an incretin hormone that stimulates the secretion of insulin from the pancreas.